Log in

NASDAQ:BWAYBRAINSWAY LTD/S Stock Price, Forecast & News

-0.08 (-1.01 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $7.81
50-Day Range
MA: $8.09
52-Week Range
Now: $7.81
Volume500 shs
Average Volume10,740 shs
Market Capitalization$84.50 million
P/E RatioN/A
Dividend YieldN/A
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation. Brainsway Ltd. was founded in 2003 and is based in Jerusalem, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:BWAY



Sales & Book Value

Annual Sales$23.10 million
Book Value$2.24 per share


Net Income$-10,330,000.00


Market Cap$84.50 million
Next Earnings Date6/3/2020 (Estimated)
OptionableNot Optionable

Receive BWAY News and Ratings via Email

Sign-up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.

BRAINSWAY LTD/S (NASDAQ:BWAY) Frequently Asked Questions

How has BRAINSWAY LTD/S's stock been impacted by COVID-19 (Coronavirus)?

BRAINSWAY LTD/S's stock was trading at $8.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BWAY stock has decreased by 4.6% and is now trading at $7.81. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of BRAINSWAY LTD/S?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BRAINSWAY LTD/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BRAINSWAY LTD/S.

When is BRAINSWAY LTD/S's next earnings date?

BRAINSWAY LTD/S is scheduled to release its next quarterly earnings announcement on Wednesday, June 3rd 2020. View our earnings forecast for BRAINSWAY LTD/S.

How were BRAINSWAY LTD/S's earnings last quarter?

BRAINSWAY LTD/S (NASDAQ:BWAY) released its quarterly earnings results on Monday, March, 23rd. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. The firm had revenue of $6.29 million for the quarter, compared to analysts' expectations of $6.25 million. BRAINSWAY LTD/S had a negative return on equity of 48.90% and a negative net margin of 44.71%. View BRAINSWAY LTD/S's earnings history.

What guidance has BRAINSWAY LTD/S issued on next quarter's earnings?

BRAINSWAY LTD/S issued an update on its first quarter 2020 Pre-Market earnings guidance on Monday, April, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.9-4.2 million, compared to the consensus revenue estimate of $5.35 million.

What price target have analysts set for BWAY?

2 Wall Street analysts have issued 1 year target prices for BRAINSWAY LTD/S's stock. Their forecasts range from $9.00 to $13.00. On average, they expect BRAINSWAY LTD/S's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 40.8% from the stock's current price. View analysts' price targets for BRAINSWAY LTD/S.

Has BRAINSWAY LTD/S been receiving favorable news coverage?

Media headlines about BWAY stock have trended negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BRAINSWAY LTD/S earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutBRAINSWAY LTD/S.

Who are some of BRAINSWAY LTD/S's key competitors?

What other stocks do shareholders of BRAINSWAY LTD/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BRAINSWAY LTD/S investors own include Gilead Sciences (GILD), Goodrich Petroleum (GDP), Goodrich Petroleum (GDP), Neuronetics (STIM), AbbVie (ABBV), Carnival (CCL), Energy Transfer LP Unit (ET), Flexion Therapeutics (FLXN), General Motors (GM) and Inovio Pharmaceuticals (INO).

Who are BRAINSWAY LTD/S's key executives?

BRAINSWAY LTD/S's management team includes the following people:
  • Dr. David Zacut, Founder & Chairman (Age 66)
  • Prof. Abraham Zangen, Founder & Member of the Scientific Advisory Board (Age 49)
  • Dr. Yiftach Roth, Founder & Chief Scientist (Age 48)
  • Mr. Hadar Levy, Chief Financial Officer (Age 45)
  • Mr. Ronen Segal, Chief Technology Officer (Age 46)


(BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at a price of $11.94 per share. Cantor served as the underwriter for the IPO.

What is BRAINSWAY LTD/S's stock symbol?

BRAINSWAY LTD/S trades on the NASDAQ under the ticker symbol "BWAY."

Who are BRAINSWAY LTD/S's major shareholders?

BRAINSWAY LTD/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cowen AND Company LLC (3.18%), Phoenix Holdings Ltd. (2.98%), Raymond James & Associates (0.17%), Victory Capital Management Inc. (0.11%), Victory Capital Management Inc. (0.11%) and Meitav Dash Investments Ltd. (0.11%).

Which major investors are selling BRAINSWAY LTD/S stock?

BWAY stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates, Meitav Dash Investments Ltd., Victory Capital Management Inc., and Victory Capital Management Inc..

Which major investors are buying BRAINSWAY LTD/S stock?

BWAY stock was bought by a variety of institutional investors in the last quarter, including Cowen AND Company LLC, and Phoenix Holdings Ltd..

How do I buy shares of BRAINSWAY LTD/S?

Shares of BWAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BRAINSWAY LTD/S's stock price today?

One share of BWAY stock can currently be purchased for approximately $7.81.

How big of a company is BRAINSWAY LTD/S?

BRAINSWAY LTD/S has a market capitalization of $84.50 million and generates $23.10 million in revenue each year. The company earns $-10,330,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. BRAINSWAY LTD/S employs 96 workers across the globe.

What is BRAINSWAY LTD/S's official website?

The official website for BRAINSWAY LTD/S is www.brainsway.com.

How can I contact BRAINSWAY LTD/S?

BRAINSWAY LTD/S's mailing address is 19 HARTUM STREET BYNET BUILDING 3RD FL Har HaHotzvim, Jerusalem L3, 9777518. The company can be reached via phone at 972-2581-3140 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.